Anaroxyl Tablet, Injection
Anaroxyl is a haemostatic with a rapid onset of action. It contains a water soluble form of adrenochrome monosemicarbazone, a stable derivative of adrenochrome as the active substance. Adrenochrome is an oxidation product of adrenaline; it reduces normal and pathologic bleeding time by decreasing capillary permeability. It produces capillary haemostatis without exerting any of the adrenergic actions on respiration or cardiovascular system. Thus, despite its adrenaline like action on small blood vessels, does not give rise to the general systemic effects of sympathomimetic drugs.
Adrenochrome is used for control capillary bleeding, haemoptysis, epistemic, haematuria, retinal hemorrhage, secondary hemorrhage from wounds
|Therapeutic Class||Anti-fibrinolytic drugs|
|Manufacturer||Nuvista Pharma Ltd, Nuvista Pharma Ltd,, Obs|
|Available Country||Bangladesh, Pakistan,|
|Last Updated:||June 23, 2021 at 11:16 am|
Table Of contents
- As a haemostatic: 10-30 mg tid.
- As a haemostatic: 10 mg daily by SC/IM inj. Alternatively, 25-100 mg daily by IV Inj or drip infusion.
- Pre-operative: 2-6 ml at suitable intervals.
- Post-operative: 1-2 ml every 2 hrs.
- Non-surgical: 2-4 ml tid.
Injection (Child <6 years): 1-2 ml tid.
Allergic reactions may occur like dyspnoea, bronchospasm, skin reaction etc.
Because of the content of diprophylline (90 mg/ml), the dosage to premature babies, infants and young children should not exceed 0.3 ml.
No specific drug interaction has been demonstrated.
Pregnancy & Breastfeeding use
Pregnancy Category-Not Classified. FDA has not yet classified the drug into a specified pregnancy category
Should not be administered to patients with hypersensitivity